Experiences of patients with heart failure with medicines at transition intervention: Findings from the process evaluation of the Improving the Safety and Continuity of Medicines management at Transitions of care (ISCOMAT) programme.


Journal

Health expectations : an international journal of public participation in health care and health policy
ISSN: 1369-7625
Titre abrégé: Health Expect
Pays: England
ID NLM: 9815926

Informations de publication

Date de publication:
10 2022
Historique:
revised: 23 06 2022
received: 20 01 2022
accepted: 11 07 2022
pubmed: 2 8 2022
medline: 1 11 2022
entrez: 1 8 2022
Statut: ppublish

Résumé

Medicines are often suboptimally managed for heart failure patients across the transition from hospital to home, potentially leading to poor patient outcomes. The Improving the Safety and Continuity Of Medicines management at Transitions of care programme included: understanding the problems faced by patients and healthcare professionals; developing and co-designing the Medicines at Transitions of care Intervention (MaTI); a cluster randomized controlled trial testing the effectiveness of a complex behavioural MaTI aimed at improving medicines management at the interface between hospitals discharge and community care for patients with heart failure; and a process evaluation. The MaTI included a patient-held My Medicines Toolkit; enhanced communication between the hospital and the patient's community pharmacist and increased engagement of the community pharmacist postdischarge. This paper reports on the patients' experiences of the MaTI and its implementation from the process evaluation. Twenty one-to-one semi-structured patient interviews from six intervention sites were conducted between November 2018 and January 2020. Data were analysed using the Framework method, involving patients as co-analysts. Interview data were triangulated with routine trial data, the Consolidated Framework for Implementation Research and a logic model. Within the hospital setting patients engaged with the toolkit according to whether staff raised awareness of the My Medicines Toolkit's importance and the time and place of its introduction. Patients' engagement with community pharmacy depended on their awareness of the community pharmacist's role, support sources and perceptions of involvement in medicines management. The toolkit's impact on patients' medicines management at home included reassurance during gaps in care, increased knowledge of medicines, enhanced ability to monitor health and seek support and supporting sharing medicines management between formal and informal care networks. Many patients perceived that the MaTI offered them support in their medicines management when transitioning from hospital into the community. Importantly, it can be incorporated into and built upon patients' lived experiences of heart failure. Key to its successful implementation is the quality of engagement of healthcare professionals in introducing the intervention. Patients were involved in the study design, as qualitative data co-analysts and as co-authors.

Sections du résumé

BACKGROUND
Medicines are often suboptimally managed for heart failure patients across the transition from hospital to home, potentially leading to poor patient outcomes. The Improving the Safety and Continuity Of Medicines management at Transitions of care programme included: understanding the problems faced by patients and healthcare professionals; developing and co-designing the Medicines at Transitions of care Intervention (MaTI); a cluster randomized controlled trial testing the effectiveness of a complex behavioural MaTI aimed at improving medicines management at the interface between hospitals discharge and community care for patients with heart failure; and a process evaluation. The MaTI included a patient-held My Medicines Toolkit; enhanced communication between the hospital and the patient's community pharmacist and increased engagement of the community pharmacist postdischarge. This paper reports on the patients' experiences of the MaTI and its implementation from the process evaluation.
DESIGN
Twenty one-to-one semi-structured patient interviews from six intervention sites were conducted between November 2018 and January 2020. Data were analysed using the Framework method, involving patients as co-analysts. Interview data were triangulated with routine trial data, the Consolidated Framework for Implementation Research and a logic model.
RESULTS
Within the hospital setting patients engaged with the toolkit according to whether staff raised awareness of the My Medicines Toolkit's importance and the time and place of its introduction. Patients' engagement with community pharmacy depended on their awareness of the community pharmacist's role, support sources and perceptions of involvement in medicines management. The toolkit's impact on patients' medicines management at home included reassurance during gaps in care, increased knowledge of medicines, enhanced ability to monitor health and seek support and supporting sharing medicines management between formal and informal care networks.
CONCLUSION
Many patients perceived that the MaTI offered them support in their medicines management when transitioning from hospital into the community. Importantly, it can be incorporated into and built upon patients' lived experiences of heart failure. Key to its successful implementation is the quality of engagement of healthcare professionals in introducing the intervention.
PATIENT OR PUBLIC CONTRIBUTION
Patients were involved in the study design, as qualitative data co-analysts and as co-authors.

Identifiants

pubmed: 35909321
doi: 10.1111/hex.13570
pmc: PMC9615069
doi:

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2503-2514

Informations de copyright

© 2022 The Authors. Health Expectations published by John Wiley & Sons Ltd.

Références

J Am Geriatr Soc. 2018 Sep;66(9):1812-1822
pubmed: 29972591
Health Expect. 2022 Oct;25(5):2503-2514
pubmed: 35909321
BMC Med Res Methodol. 2013 Sep 18;13:117
pubmed: 24047204
J Hosp Med. 2012 May-Jun;7(5):382-7
pubmed: 22378714
Ann Behav Med. 2019 Jul 17;53(8):693-707
pubmed: 30304386
BMJ Open. 2022 Apr 29;12(4):e054274
pubmed: 35487708
J Am Heart Assoc. 2016 Jun 17;5(6):
pubmed: 27317347
Res Social Adm Pharm. 2021 Dec;17(12):2127-2135
pubmed: 34187746
Health Expect. 2018 Apr;21(2):409-428
pubmed: 29114971
Res Social Adm Pharm. 2021 Apr;17(4):750-762
pubmed: 32800714
Patient Prefer Adherence. 2016 Sep 09;10:1749-58
pubmed: 27672313
BMJ Open. 2020 Nov 24;10(11):e040493
pubmed: 33234644
BMJ Open. 2019 Feb 19;9(2):e023440
pubmed: 30782879
BMJ Open. 2018 May 5;8(5):e019101
pubmed: 29730617
Ann Behav Med. 2013 Aug;46(1):81-95
pubmed: 23512568
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Health Expect. 2020 Jun;23(3):562-570
pubmed: 32045087
Lancet. 2018 Feb 10;391(10120):572-580
pubmed: 29174292

Auteurs

Catherine Powell (C)

School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.
Wolfson Centre for Applied Health Research, Bradford, UK.

Hanif Ismail (H)

Leeds Teaching Hospitals NHS Trust, Research and Innovation Centre, Leeds, UK.

Maureen Davis (M)

ISCOMAT Patient-Led Steering Group, University of Bradford, Bradford, UK.

Andrew Taylor (A)

ISCOMAT Patient-Led Steering Group, University of Bradford, Bradford, UK.

Liz Breen (L)

School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.
Wolfson Centre for Applied Health Research, Bradford, UK.
NIHR Yorkshire and Humber Patient Safety Translational Research Centre, Bradford Institute for Health Research, Bradford, UK.

Beth Fylan (B)

School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.
Wolfson Centre for Applied Health Research, Bradford, UK.
NIHR Yorkshire and Humber Patient Safety Translational Research Centre, Bradford Institute for Health Research, Bradford, UK.

Sarah L Alderson (SL)

School of Medicine, University of Leeds, Leeds, UK.

Chris P Gale (CP)

Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Leeds Institute for Data Analytics, University of Leeds, Leeds, UK.
Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Ian Kellar (I)

School of Psychology, University of Leeds, Leeds, UK.

Jonathan Silcock (J)

School of Pharmacy and Medical Sciences, University of Bradford, Bradford, UK.
Wolfson Centre for Applied Health Research, Bradford, UK.

David P Alldred (DP)

Wolfson Centre for Applied Health Research, Bradford, UK.
NIHR Yorkshire and Humber Patient Safety Translational Research Centre, Bradford Institute for Health Research, Bradford, UK.
School of Healthcare, University of Leeds, Leeds, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH